Using antibody synergy to engineer a high potency biologic cocktail against C. difficile
Zhao, H.; Tasch, M.; Dodds, M.; Gewe, M.; Martinez, A.; Hutton, M.; Keeney, K.; Pollock, A.; Jester, B.; Khuong, N.; Zhang, M.; Brady, C.; Heinnickel, M.; Tabakh, H.; Sanjaya, N.; Cruickshank, K.; Paddock, T.; Ertel, S.; Struyvenberg, S.; Dang, J.; Shanitta, C.; Fletcher, D.; Goetsch, L.; Gamble, C.; Mileto, S.; Heselpoth, R.; Lyras, D.; Behnke, C.; Fischetti, V.; Finrow, B.; Roberts, J. M.
Show abstract
Drugs which independently inhibit a shared target or pathway can have synthetic activities that result in multiplicative instead of merely additive potencies. This characteristic of drug combinations can be quantified by expressing the potency of the combination as if it were a single agent. We show that by optimizing this quantity we can prospectively design drug cocktails with apparent potencies that far exceed any of its individual components. We illustrate the power of this approach, which is based on statistical design of experiments to select optimal drug combinations, and response surface methodology to determine optimal drug ratios, by building a drug cocktail comprised of three antibodies for treating C. difficile infection that is almost 1000-fold more potent than the current, clinically approved antibody monotherapy. High synthetic activities do not require unusual drug interactions, and therefore may be achievable much more readily than generally appreciated. One-Sentence SummaryA development pathway is described for designing antibody cocktails with potencies that far exceed what is achievable with single antibodies
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Single domain antibodies against enteric pathogen virulence factors are active as curli fiber fusions on probiotic E. coli Nissle 1917 95%
- Glucosyltransferase-dependent and independent effects of Clostridioides difficile toxins during infection 95%
- Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B 94%
Similar papers in this journal
- Assessment of chemical methods in the extraction of spore surface layers in Clostridioides difficile spores 94%
- Clostridioides difficile-mucus interactions encompass shifts in gene expression, metabolism, and biofilm formation 94%
- Degradation of the incretin hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis metalloprotease GelE 93%
Similar papers in this journal
- Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies 95%
- A ligated intestinal loop mouse model protocol to study the interactions of Clostridioides difficile spores with the intestinal mucosa during aging. 92%
- Identification of the Clostridial cellulose synthase and characterization of the cognate glycosyl hydrolase, CcsZ 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.